Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma's stock price has declined significantly by approximately -72.71% over the past six months. The company received a notice from NYSE American indicating non-compliance with continued listing standards on April 3, 2026. On March 31, 2026, Matinas BioPharma announced staff reductions and is actively seeking a partner for MAT2203. Jerome D. Jabbour was appointed interim Chief Financial Officer on January 23, 2026. The company amended its CEO contract to include extended change-in-control bonus protections on December 12, 2025. Matinas BioPharma announced a planned CFO departure on November 21, 2025.

Matinas BioPharma Holdings, Inc. does not experience traditional product or service demand seasonality in the commercial sense. The company's progress and financial needs are more influenced by the cyclical nature of clinical trials, regulatory milestones, and funding rounds, which do not typically follow a predictable seasonal pattern.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies using its lipid nanocrystal (LNC) platform delivery technology. The company aims to improve the intracellular delivery of small molecules and oligonucleotides to enhance the safety, reduce toxicity, improve tolerability, and enable oral bioavailability of therapeutics. Its major product candidates include MAT2203 and MAT2501, and the company is pursuing additional discovery programs in oncology and inflammation, collaborating with organizations such as the National Institute of Allergy and Infectious Diseases, BioNTech SE, and Genentech Inc.

Matinas BioPharma Holdings, Inc. is based in Bedminster, New Jersey, United States, where its primary operations and development activities are centered.

Matinas BioPharma's brand reputation has been influenced by both positive and negative developments. Positive influences include the announcement of positive in vivo safety data for its oral LNC-Docetaxel formulation in March 2026, and the appointment of experienced biotech leaders and new members to its Board of Directors in early 2025. Negative influences include the recent notice of non-compliance with NYSE American listing standards in April 2026, coupled with multi-year losses and an auditor's report raising substantial doubt about the company's ability to continue as a going concern.

The ownership structure of Matinas BioPharma (MTNB) includes institutional, insider, and retail investors. Institutional investors hold approximately 1.43% to 7.75% of the company's stock, while insiders hold around 11.5% to 32.75%. Retail investors own a significant portion, ranging from 67.25% to 83.51%. Major institutional owners include Citadel Advisors Llc, Vanguard Group Inc, Geode Capital Management, Llc, and BlackRock, Inc. Jerome D. Jabbour (President and CEO) and other individual insider shareholders, including Adam K. Stern, Herbert J. Conrad, and Roelof Rongen, own a substantial number of shares.